CD3: differenze tra le versioni

Versione delle 10:32, 17 gen 2022

Versione delle 21:49, 16 apr 2022

Riga 36:

*{{Cita pubblicazione | autore=Joseph AM, Kumar M, Mitra D |titolo=Nef: "necessary and enforcing factor" in HIV infection. |rivista=Curr. HIV Res. |volume=3 |numero= 1 |pp=87–94 |anno= 2005 |pmid=15638726 |doi=10.2174/1570162052773013 }}

*{{Cita pubblicazione | autore=Li CJ |titolo=Therapeutic biology: checkpoint pathway activation therapy, HIV Tat, and transkingdom RNA interference. |rivista=J. Cell. Physiol. |volume=209 |numero= 3 |pp=695–700 |anno= 2007 |pmid=17001685 |doi= 10.1002/jcp.20817 }}

*{{Cita pubblicazione | autore=Luzzati AL, Giacomini E, Giordani L, ''et al.'' |titolo=The antigen-specific induction of normal human lymphocytes in vitro is down-regulated by a conserved HIV p24 epitope. | url=https://archive.org/details/sim_immunology-letters_1992-08_33_3/page/307 |rivista=Immunol. Lett. |volume=33 |numero= 3 |pp=307–14 |anno= 1992 |pmid=1385321 |doi=10.1016/0165-2478(92)90078-3 }}

*{{Cita pubblicazione | autore=Lanier LL, Chang C, Spits H, Phillips JH |titolo=Expression of cytoplasmic CD3 epsilon proteins in activated human adult natural killer (NK) cells and CD3 gamma, delta, epsilon complexes in fetal NK cells. Implications for the relationship of NK and T lymphocytes. |rivista=J. Immunol. |volume=149 |numero= 6 |pp=1876–80 |anno= 1992 |pmid=1387664 }}

*{{Cita pubblicazione | autore=Letourneur F, Klausner RD |titolo=A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. |rivista=Cell |volume=69 |numero= 7 |pp=1143–57 |anno= 1992 |pmid=1535555 |doi=10.1016/0092-8674(92)90636-Q }}